Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03088527 · ClinicalTrials.gov registry record · Phase 1
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
A Phase 1 study, sponsored by Stemline Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03088527 is a Phase 1 study that has completed, run by Stemline Therapeutics. The registered enrollment target is 20 participants.
The verdict
NCT03088527, a Phase 1 study, has completed, sponsored by Stemline Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Interventions
- DRUG RAD140
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-23 |
| Est. Completion | 2020-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03088527
The ClinicalTrials.gov registry entry for NCT03088527 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD140 is the first listed.
NCT03088527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03088527 about?
NCT03088527 is a clinical study titled "Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer". The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
What is the current status of trial NCT03088527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-10-23. Estimated completion is 2020-09-24.
What interventions are being tested in trial NCT03088527?
The interventions under investigation include: RAD140 (DRUG).
Who is sponsoring clinical trial NCT03088527?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.